Alkylating Prodrugs in Cancer Chemotherapy

  • T. A. Connors
Part of the Developments in Pharmacology book series (DIPH, volume 3)


The concept of the design of latently active drugs (or prodrugs), that is chemicals which are not themselves active but which require conversion to their active form has been well established for many years and has been used with success in many areas of therapy.


Alkylating Agent Hypoxic Cell Nitrogen Mustard Anti Tumour Ischaemic Zone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Seligman AM, Nachlas MM, Manheimer LHI, Friedman OM, Wolf G. 1949. Ann. Surg. 130 333.CrossRefGoogle Scholar
  2. 2.
    Ishidate M, Sakurai T, Yoshida T, Sato H, Matui E. 1953. GANN 44, 342.Google Scholar
  3. 3.
    Ross WCJ. 1962. Biological Alkylating Agents, London. Butterworth Press.Google Scholar
  4. 4.
    Connors TA. 1976. in Progress in Drug Metabolism, eds Bridges JW, Chasseaud LF. Wiley, New York, pp41–75.Google Scholar
  5. 5.
    Cox PJ, Farmer PB. 1977. Cancer Treatment Reviews, 4, 47 and 119.PubMedCrossRefGoogle Scholar
  6. 6.
    Connors TA, Cox PJ, Farmer PU, Foster AB, Jarman M. 1974. Biochem. Pharmacol. 23, 115.PubMedCrossRefGoogle Scholar
  7. 7.
    Connors TA, Whisson ME. 1966. Nature 210, 866.PubMedCrossRefGoogle Scholar
  8. 8.
    Young CW, Yagoda A, Bittar ES, Smith SW, Grabstald H, Whitmore W. 1976. Cancer 38, 1887.Google Scholar
  9. 9.
    Stanners CP, Lam T, Chamberlain JW, Stewart SS, Price GB. 1981. Cell 27, 211.PubMedCrossRefGoogle Scholar
  10. 10.
    Cater DB. 1964. Tumori 50. 435.PubMedGoogle Scholar
  11. 11.
    Lin AJ, Cosby LA, Shansky CW, Sartorelli AC. 1972. J. Med. Chem. 15, 1247.PubMedCrossRefGoogle Scholar
  12. 12.
    Moore HW, Czerniak R. 1981. Med Res. Rev. 1, 249.PubMedCrossRefGoogle Scholar
  13. 13.
    Goldacre RJ, Sylven B. 1962. Brit. J. Cancer 16, 306.PubMedCrossRefGoogle Scholar
  14. 14.
    Goldacre RJ, Whisson ME. 1966. Brit.J.Cancer, 20, 801.PubMedCrossRefGoogle Scholar
  15. 15.
    Chapman JD, Franko AJ, Sharplin J. 1981. Brit. J. Cancer, 43, 546.PubMedCrossRefGoogle Scholar
  16. 16.
    Franko AJ, Chapman JD. 1982. Brit. J. Cancer, 45, 694.PubMedCrossRefGoogle Scholar
  17. 17.
    Farber W, Toch R, Sears EM, Pinkel D. 1960. Acta Un. int. Cancr, 16 611.Google Scholar
  18. 18.
    Carl PL, Chakravarty PK, Katzenellenbogen JA, Weber MJ. 1980. Pro. Natl. Acad. Sci. 77. 2224.CrossRefGoogle Scholar
  19. 19.
    Slater TF, White W. Personal Communication.Google Scholar
  20. 20.
    Fiala S, Fiala ES. 1973. J. Natl. Cancer Inst., 51, 151.PubMedGoogle Scholar
  21. 21.
    Rosalki SB. 1975. Adv. Clin. Chem., 17, 53.PubMedCrossRefGoogle Scholar
  22. 22.
    Peters TJ, Seymour CA, Wells G, Fakunle F, Neale G. 1977. Br. Med. J., i, 1576.Google Scholar
  23. 23.
    Manson MM, Legg RF, Watson JV, Green JA, Neal GE. 1981. Carcinogenesis 2, 661.PubMedCrossRefGoogle Scholar
  24. 24.
    Politzer P, Trefonas P. 1980. in Carcinogenesis. Fundamental mechanisms and environmental effects. eds. Pullman B, Tso POP, Gelboin H. Dordrecht, Boston, London. D Reidel publishing company, pp67–79.Google Scholar
  25. 25.
    Kuochan SM, Schubert RM. 1974. Science 185, 791.CrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, The Hague, Boston, London 1983

Authors and Affiliations

  • T. A. Connors

There are no affiliations available

Personalised recommendations